Selective mAChR M4 Antagonists for Parkinson's Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease, such as levodopa and muscarinic acetylcholine receptor antagonists, have limitations including adverse effects and inadequate dosage due to non-selectivity, which restricts their clinical utility and potential efficacy.
Innovation Solution
Development of compounds, specifically substituted octahydropyrrolo[3,4-b]pyrrole derivatives, that act as selective antagonists for the muscarinic acetylcholine receptor M4 (mAChR M4), potentially offering improved antiparkinsonian effects with reduced adverse effects by targeting specific mAChR subtypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective mAChR antagonists are used to treat Parkinson's disease, then antiparkinsonian effects are achieved, but adverse effects and cognitive disturbances occur that limit clinical utility
Solution Approach 1:
The patent applies segmentation by dividing the non-selective mAChR antagonism into selective subtype-specific antagonism. The compounds are designed to selectively block M4 mAChR subtype while sparing other subtypes (M1-M3, M5), thereby segmenting the therapeutic effect from adverse effects. This selective blockade targets the specific receptor subtype responsible for motor control in the basal ganglia while avoiding subtypes involved in peripheral and cognitive functions.
Solution Approach 2:
The patent implements local quality by confining the pharmacological action to a specific receptor subtype (M4) in the central nervous system, particularly in the striatum and basal ganglia. The compounds exhibit preferential binding to M4 receptors in these motor control regions, providing localized therapeutic effect while minimizing systemic and cognitive side effects associated with broader receptor blockade.
2Reliability
If doses of mAChR antagonists are increased to achieve more complete blockade, then antiparkinsonian efficacy is improved, but adverse effects increase that limit tolerability
Solution Approach 1:
The patent resolves this contradiction by segmenting the receptor blockade to target only M4 subtype, allowing for effective therapeutic doses without the cumulative adverse effects of non-selective antagonism. This selective approach enables higher effective blockade of the motor-control relevant M4 receptors while maintaining tolerability by sparing other receptor subtypes that mediate side effects.
Solution Approach 2:
The patent applies parameter changes by modifying the selectivity profile of the antagonist compounds. The compounds are designed with specific molecular structures (e.g., substituted octahydropyrrolo[3,4-b]pyrrole derivatives) that confer preferential binding to M4 receptors, changing the pharmacological parameter of receptor selectivity to achieve better therapeutic index and dose tolerability.
3Quantity of substance
If non-selective mAChR antagonists are used, then broad receptor blockade is achieved, but selectivity for M4 subtype is insufficient leading to peripheral and cognitive side effects
Solution Approach 1:
The patent implements local quality by designing compounds with specific molecular features that confer selective affinity for M4 mAChR subtype. The substituted octahydropyrrolo[3,4-b]pyrrole core structure, along with specific substituents (e.g., adamantyl, aryl, heteroaryl groups), creates a pharmacophore that selectively interacts with M4 receptors in the basal ganglia, providing precise subtype targeting while maintaining adequate blockade coverage for therapeutic effect.
Solution Approach 2:
The patent applies parameter changes by optimizing the selectivity parameter through molecular structure design. The compounds exhibit selective binding characteristics with preferential affinity for M4 receptors compared to other mAChR subtypes, achieved through specific structural modifications including the pyrrolo[3,4-b]pyrrole core and various substituent patterns that match the M4 receptor binding pocket geometry and chemistry.
Data Source
AI summary
Disclosed herein are octahydropyrrolo[3,4-b]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.